EMVI call 2003
Var2-CSA DBL3-X and Var2CSA

EMVI call 2002
Polyprotein FP9 PP and MVA PP, Phase Ia Oxford
GMZ2 Phase Ia Tübingen
GMZ2 Phase Ib in adults and children Gabon (AMANET)
GMZ2 remains with Statens Serum Institut
During 2009 EMVI became a separate legal entity in its own right registered in Germany and is now known as European Vaccine Initiative - EEIG.  EMVI, in collaboration with its partners, was successful in 2009 negotiating a five year contract with EDCTP, coordinated by AMANET, for the funding of the project entitled “Fostering Research Capacity, Networking and Project Management through Phase I-IIb Clinical Trials of Candidate Malaria Vaccine GMZ2”. As the title suggests, the project involves Phase II clinical trials of GMZ2 at several African sites. As the mandate of EMVI was primarily to develop experimental malaria vaccines up to Phase II clinical evaluation, GMZ2 will remain with Statens Serum Institut. It is the sincere hope of EVI-EEIG that Statens Serum Institut will be able to commit the resources necessary to continue the highly successful work of EMVI in the development of this promising malaria vaccine candidate, and to make it available to Developing Countries if the EDCTP project is successful.

EMVI call 2000
PfAMA1 Phase Ia Nijmegen
PfAMA1 - ASO2A Phase Ib Mali

EMVI call 1998
PfMSP3 as LSP, Phase Ia Lausanne
PfGLURP as LSP, Phase Ia, Nijmegen
PfMSP3 as LSP, PhaseIb, Burkina Faso

EDCTP call 2007 - GMZ2 Consortium
GMZ2 remai8ns with Statens Serum Institut - read above